Cargando…
AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors
Dysregulation of the receptor tyrosine kinase AXL is known to promote cancer cell growth and survival in many sarcomas, including the rare subtype, malignant peripheral nerve sheath tumors (MPNST). MPNSTs are largely chemoresistant and carry a poor prognosis. AXL is an attractive potential therapeut...
Autores principales: | Landers, Sharon M., Bhalla, Angela D., Ma, XiaoYan, Lusby, Kristelle, Ingram, Davis, Al Sannaa, Ghadah, Wang, Wei-Lien, Lazar, Alexander J., Torres, Keila E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717506/ https://www.ncbi.nlm.nih.gov/pubmed/33283192 http://dx.doi.org/10.26502/jcsct.5079091 |
Ejemplares similares
-
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas
por: May, Caitlin D., et al.
Publicado: (2015) -
Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway
por: Zhang, Pingyu, et al.
Publicado: (2015) -
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma
por: May, Caitlin D., et al.
Publicado: (2017) -
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
por: Nagabushan, Sumanth, et al.
Publicado: (2021) -
Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
por: Gu, Yihui, et al.
Publicado: (2022)